A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes (Q35143275)

6 August 2017

title

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes (English)

1 reference

6 August 2017

14

Hagop Kantarjian

1 reference

6 August 2017

3

Elias Jabbour

1 reference

6 August 2017

Guillermo Garcia-Manero

1

object named as

Guillermo Garcia-Manero

1 reference

6 August 2017

4

Jeffrey Lancet

1 reference

6 August 2017

2

Hanna J Khoury

1 reference

6 August 2017

13

Alan List

1 reference

6 August 2017

15

Rami Komrokji

1 reference

6 August 2017

7

Selena Rush

1 reference

6 August 2017

10

Mieke Ptaszynski

1 reference

6 August 2017

11

Monica Cabrero Calvo

1 reference

6 August 2017

12

Zach Bohannan

1 reference

6 August 2017

Shannon L Winski

5

1 reference

6 August 2017

LouAnn Cable

6

1 reference

6 August 2017

Lara Maloney

8

1 reference

6 August 2017

Grant Hogeland

9

1 reference

6 August 2017

language of work or name

English

0 references

publication date

5 December 2014

1 reference

6 August 2017

published in

Clinical Cancer Research

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

985-994

1 reference

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Toll-like receptor alterations in myelodysplastic syndrome

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Revised international prognostic scoring system for myelodysplastic syndromes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Management of lower-risk myelodysplastic syndromes: the art and evidence.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Targeting the ANGPT-TIE2 pathway in malignancy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Cause of death in patients with lower-risk myelodysplastic syndrome

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

The World Health Organization (WHO) classification of the myeloid neoplasms

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

International scoring system for evaluating prognosis in myelodysplastic syndromes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Myelodysplastic syndromes

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348327

Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome

16 November 2018

1 reference

12 December 2020

Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells

1 reference

12 December 2020

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

1 reference

12 December 2020

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

12 December 2020

Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome

1 reference

12 December 2020

10.1158/1078-0432.CCR-14-1765

Identifiers

DOI

1 reference

release_mtsblmzmljfexm4yg76gqouuoy

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mtsblmzmljfexm4yg76gqouuoy

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4348327

1 reference

6 August 2017

1 reference